

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/206636 A1

(51) International Patent Classification:

C07K 16/10 (2006.01) G01N 33/53 (2006.01)
A61K 39/42 (2006.01) A61P 31/14 (2006.01)

(21) International Application Number:

PCT/SG2021/050195

(22) International Filing Date:

07 April 2021 (07.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202003204P 07 April 2020 (07.04.2020) SG
10202004828Q 22 May 2020 (22.05.2020) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **WANG, Cheng-I**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **WANG, Bei**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **NGOH, Zi Xian Eve**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **LEE, Wen-Hsin**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **HU, Yuanyu**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **LEE, Chia Yin**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **TAN, Hwee Ching**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **NG, Patricia Miang Lon**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **MIN-HAT, Rabiatal Adawiyah Binte**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **HUANG, Ching-Wen**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **SOH, Mun Kuen**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **YEAP, Yee Chin, Yvonne**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG). **TEO, Jiuyi Frannie**; c/o Singapore Immunology Network, 8A Biomedical Grove, 03-06, Singapore 138648 (SG).

(74) Agent: **DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ANTIGEN-BINDING PROTEIN TO SARS-CoV-2

(57) Abstract: The present invention relates to provide antigen-binding proteins that are capable of binding to and/or neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In one embodiment, the antigen-binding proteins are capable of binding to a spike protein of SARS-CoV-2 including receptor-binding domain (RBD) of SARS-CoV-2. The present invention also provides products comprising the same and methods of using the same for the treatment of SARS-CoV-2 infection or for detecting the presence of SARS-CoV-2 in a sample.



WO 2021/206636 A1